STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
chemistry

Rallybio Collaborates with Johnson & Johnson to Tackle Rare Disease FNAIT

byLiliana Vida
April 11, 2024
in Biotechnology, Small-Cap
Reading Time: 1 min read
Share on TwitterShare on LinkedIn

Partnership Aims to Develop Therapeutic Solutions for Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (RLYB) has announced a collaboration with Johnson & Johnson to advance therapeutic approaches for reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). This collaboration includes a $6.6 million equity investment from Johnson & Johnson Innovation – JJDC, Inc.

Rallybio’s focus lies in developing RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing, thereby mitigating the risk of FNAIT in fetuses and newborns. With plans to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024, Rallybio aims to address the critical need for preventative treatment options in individuals at higher risk of FNAIT.

The collaboration with Johnson & Johnson involves funding to raise awareness of Johnson & Johnson’s FNAIT clinical program alongside Rallybio’s ongoing natural history study. Together, the companies aspire to drive awareness, screening, and therapeutic advancements to combat FNAIT, ultimately improving outcomes for affected individuals.

Read original press release:here

You might like this article:Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal

Previous Post

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal

Next Post

Candel Therapeutics’ CAN-2409 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Related Posts

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

byLuca Blaumann
August 14, 2025
0

Frontier technology firm posts strong top-line growth, boosts BTC portfolio, and advances R&D in energy systems and robotics KULR Technology...

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

byLuca Blaumann
August 5, 2025
0

Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...

ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug

byLiliana Vida
July 21, 2025
0

PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...

Next Post
chemistry-2

Candel Therapeutics' CAN-2409 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

Intel Shares Surge After $2 Billion SoftBank Investment

Strategy Expands Bitcoin Holdings With $51 Million Purchase

Based on Your Interest

Aerospace & Defense

Amphenol Expands Defense Portfolio With $1 Billion Trexon Acquisition

August 18, 2025
investing
Insurance

Buffett Bet Sends UnitedHealth Shares Soaring

August 18, 2025
Small-Cap

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

August 14, 2025

Recommended

Financial Services

Berkshire Hathaway Adds New Stakes Across Healthcare, Industrials, and Real Estate

August 14, 2025
Pharmaceuticals

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

August 14, 2025
Large-Cap

Ulta and Target to End Mini-Store Partnership in 2026

August 14, 2025
Airlines

Spirit Aviation Warns of Possible Collapse as Cash Runs Low

August 13, 2025
Large-Cap

Cava Shares Plunge as Chain Cuts Same-Store Sales Outlook

August 12, 2025
Stoxpo

Follow us on social media:

Highlights

  • Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual
  • Intel Seeks More Equity Infusions Amid Mounting Financial Strains
  • Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
  • Intel Shares Surge After $2 Billion SoftBank Investment
  • Strategy Expands Bitcoin Holdings With $51 Million Purchase

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

August 21, 2025

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

August 20, 2025
scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

August 19, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?